<DOC>
	<DOC>NCT00821977</DOC>
	<brief_summary>This is a 2-3 period parallel group study with an adaptive element in Type 2 diabetes patients receiving vildagliptin as monotherapy.</brief_summary>
	<brief_title>Efficacy and Long-Term Safety of Vildagliptin as Monotherapy in Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<criteria>Patients at least 18 years of age at Visit 1 Drug naïve patients with T2DM diagnosed at least 2 months prior to Visit 1 HbA1c ≥ 7.0 % and ≤ 10.0% at Visit 1 Body Mass Index (BMI) in the range of 2245 kg/m2 at Visit 1 Pregnant or lactating female FPG ≥ 270 mg/dL (≥15 mmol/L) Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Type 2 Diabetes</keyword>
	<keyword>Vildagliptin</keyword>
</DOC>